It is controversial whether chemotherapy with or without primary tumour resection is effective for the patients with incurable Stage IV colorectal cancer. A randomized controlled trial, initiated in Japan in 2012, is being conducted to evaluate the survival benefit and safety of primary tumour resection plus chemotherapy compared with chemotherapy alone in asymptomatic Stage IV colorectal cancer patients with unresectable metastatic disease. Patients are randomly assigned to either chemotherapy alone or primary tumour resection followed by chemotherapy. The primary endpoint is overall survival. Secondary endpoints are progression-free survival, incidence of adverse events, proportion of patients with R0 resection and proportion of palliative surgery for the chemotherapy-alone group. This trial was registered in June 2012 with the UMIN Clinical Trials Registry as UMIN000008147 [http://www.umin.ac.jp/ctr/index-j.htm]. In December 2017, the study protocol was amended for reducing sample size. A total of 280 patients will be enrolled over the course of 8.5 years.
Background and rationale
Colorectal cancer (CRC) is one of the major leading causes of death from cancer worldwide (1) . With the introduction of new chemotherapeutic agents, survival of Stage IV CRC patients has improved substantially. However, at the time of diagnosis, the majority of patients with Stage IV disease have unresectable tumours and can only undergo palliative treatment. For patients with a symptomatic primary tumour (e.g. anaemia, obstruction and infection), surgical resection or a diverting stoma may be necessary. For patients with both unresectable metastatic disease and an asymptomatic primary tumour, the initial treatment strategy is controversial. Some have reported that the benefits of primary tumour resection on overall survival are unclear and that morbidity and mortality related to tumour resection should be avoided because a delay in initiating chemotherapy can have a negative impact on survival (2, 3) . However, others have reported that the strategy for managing CRC patients with unresectable metastases is based on the beneficial effects of chemotherapy on both metastatic disease and the primary tumour in patients with good performance status (3, 4) .
Conversely, many studies reported that resection of primary tumour is necessary in patients with unresectable distant metastases and an asymptomatic primary tumour (5, 6) . Primary tumour resection could prevent intestinal complications, such as obstruction, bleeding, perforation or fistula (6) . These complications are associated with poor oncologic outcomes as well as perioperative morbidity and mortality. Moreover, recent papers have reported significantly better overall survival for patients undergoing primary tumour resection than patients who do not have this treatment (5) . Stillwell et al. reported that there is an improvement in the survival of patients managed with palliative resection of their primary tumour, with an estimated standardized median difference of 6.0 months by meta-analysis based on eight retrospective studies (HR = 0.55; 95% confidence interval (CI), 0.29-0.82; P < 0.001) (7) .
However, previous studies support each opposing conclusion, and these studies are all retrospective. There is still considerable uncertainty if CRC patients who present with incurable disease and little or no symptoms should undergo resection of the primary tumour prior to systemic therapy. A randomiz'ed controlled trial is required for this reason. Thus, we have designed a clinical trial. At about the same time or later when we started this trial, there is much anticipation regarding the results of several ongoing randomized controlled trials, which are summarized in Table 1 (i.e. SYNCHRONOUS in Germany (8) , CAIRO4 in the Netherlands (9), CCRe-IV in Spain (10), CLIMAT in France (11), PTR Trial in Korea (12) , Multicenter trial in China (13)). Thus, elucidating clinical significance of primary tumour resection for this patient population is an important unmet need worldwide.
Our hypothesis for the trial is that primary tumour resection for incurable Stage IV CRC in asymptomatic patients might improve compliance with the protocol treatment, helping to prevent adverse events of chemotherapy and improve survival compared with chemotherapy alone. Compared with irinotecan regimen or combination regimen with cetuximab, the rationale for choosing mFOLFOX or CapeOX plus bevacizumab as the treatment arm for this trial is based on the results from previous studies that targeted incurable Stage IV patients (14) . Oxaliplatin-based therapy is already a standard first-line treatment for metastatic unresectable CRC and is the most convenient of available regimens as it can be administered on an outpatient basis (15) .
The study protocol was designed by the Colorectal Cancer Study Group of the Japan Clinical Oncology Group (JCOG) and was approved by the JCOG Protocol Review Committee in April 2012. This trial was registered in June 2012 with the UMIN Clinical Trials Registry as UMIN000008147 (http://www.umin.ac.jp/ctr/indexj.htm). Here we provide details on the amended protocol after monitoring in December 2017 (see "Protocol Amendment").
Protocol digest of JCOG1007
Purpose The purpose of this trial was to confirm the superiority of primary tumour resection plus chemotherapy to chemotherapy alone in asymptomatic Stage IV CRC patients with synchronous incurable metastatic disease.
Study setting
This trial is a multi-institutional, randomized controlled phase III trial.
Endpoints
The primary endpoint is overall survival, defined as the time from randomization to death from any cause, and secondary endpoints are progression-free survival, incidence of adverse events, proportion of patients with R0 resection and proportion of patients with palliative surgery. Adverse events and postoperative complications were assessed in accordance with the Common Terminology Criteria for Adverse Events (version 4.0).
Eligibility criteria
CRC is classified according to the seventh edition of the Japanese Classification of Colon and Rectal Carcinoma (16) and the seventh edition of TNM classification (17) . Prior to enrolment in this trial, patients must meet all of the following criteria:
(i) Pathologically proven adenocarcinoma or adenosquamous carcinoma.
(ii) Primary tumour located in the caecum, ascending colon, transverse colon, descending colon, sigmoid colon, rectosigmoid colon or upper rectum. 
Exclusion criteria
Prior to enrolment in this trial, patients must not meet any of the following criteria: 
Randomization
Following confirmation of eligibility using the web-based system of the JCOG Data Center, patient is randomized to either chemotherapy alone or primary tumour resection followed by modified FOLFOX6 (mFOLFOX6) plus bevacizumab or CapeOX plus bevacizumab. The minimization method is used for the randomization of patients, thereby balancing the arms of the study according to institution, sex (male vs female), tumour location (colon and RS vs Ra) and performance status (0 vs 1).
Treatment methods
Chemotherapy-alone group. mFOLFOX or CapeOX regimen is selected individually before randomization with using the web-based system of the JCOG Data Center.
One course of mFOLFOX6 plus bevacizumab consists of an intravenous injection of bevacizumab 5 mg/kg over more than 10 minutes and oxaliplatin 85 mg/m 2 with leucovorin 200 mg/m 2 over 2 h followed by a fluorouracil 400 mg/m 2 bolus and 2400 mg/m 2 continuous infusion over 46 h repeated every 2 weeks. The course of CapeOX plus bevacizumab consists of an intravenous injection of bevacizumab 5 mg/kg over more than 10 minutes, oxaliplatin 130 mg/m 2 over 2 h and oral intake of capecitabine 1000 mg/m 2 twice a day for 14 days repeated every 3 weeks.
Primary tumour resection followed by chemotherapy group
After primary tumour resection, postoperative chemotherapy with mFOLFOX6 (or CapeOX) plus bevacizumab will be initiated between days 8 and 56 after surgery and repeated every 2 weeks (or 3 weeks), in the same manner as described for the chemotherapyalone group (Fig. 1 ).
Follow-up
Patient is followed up every 8 weeks until disease progression or death. Follow-up evaluations include a clinical examination, blood cell count, serum chemical tests, carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) as tumour marker tests and enhanced thoracic and abdominal/pelvic CT at 8-week intervals.
Study design and statistical methods (at the initiation of the study)
This trial is designed to confirm the superiority of primary tumour resection followed by chemotherapy to chemotherapy alone in terms of overall survival. At the initiation of the study, we hypothesized that the median survival time (MST) of the primary tumour resection and postoperative chemotherapy arm will be greater than that of the chemotherapy-alone arm of 20 months by 4 months (hazard ratio = 0.83). If the OS is significantly longer with primary tumour resection and postoperative chemotherapy compared with chemotherapy alone, primary tumour resection will be recommended as the standard treatment for incurable Stage IV colorectal cancer. According to the method of Schoenfeld and Richter (18) , the required sample size will be 758 patients (379 patients per arm), with a one-sided alpha level of 5% and a power of 75% and with 647 events expected to occur during the 5 years of accrual and the 3 years of follow-up. Given that some patients will likely be lost to follow-up, the total target sample size is set at 770 patients.
However, as of October 2017, 5 years and 4 months after the beginning of enrolment, only 18.6% (143 of 770) patients had been enrolled, and at this pace, it would take more than 15 years to reach the enrolment goal. Therefore, we reviewed the study design, including the likelihood of study completion, and concluded that the following amendments could be made:
(1) Change the add-on effect of the test treatment on the standard treatment from 4 to 8 months based on two similar overseas studies, the CAIRO4 (Holland) (12) and the SYNCHRONOUS (Germany) study (11) and recommended add-on effect of the test treatment on the standard treatment standard difference (19, 20) .
(2) Change the MST of the standard treatment group from 20 to 24 months because it became relevant that MST of the standard treatment was higher than expected. (3) Change the power from 75 to 70% considering the feasibility.
The required sample size of 268 was calculated with hazard ratio of 0.75, which corresponded to MST of 24 months vs. 32 months, an accrual period of 7 years (1.5-year extension), a follow-up period of 3 years, α = 5% (one-sided) and a power of 70%. Although the required sample size is 268 patients (227 events) in total in both groups, the planned sample size is 280 considering a few lost followup patients.
Interim analysis and monitoring
We plan to conduct two interim analyses. The first interim analysis will be conducted after half of the planned number of patients has been enrolled. The second interim analysis will be conducted after the completion of patient accrual. The multiplicity will be adjusted using the Lan-DeMets method with the O'Brien-and Fleming-type alphaspending function (21) . The Data and Safety Monitoring Committee of the JCOG will independently review the interim analysis reports and determine if the trial should be terminated early. The JCOG Data Center and study coordinator will conduct central monitoring and issue a monitoring report every 6 months to evaluate study progress and improve data integrity and patient safety. For quality assurance, site-visit audits will be performed by the JCOG Audit Committee (not on a study-specific basis but for the study group).
Clinical trials registry
This trial was registered with the UMIN Clinical Trials Registry as UMIN000008147 (http://www.umin.ac.jp/ctr/index-j.htm).
Participating institutions (in order of geographical location from north to south Japan) Sapporo-Kosei General Hospital, Iwate Medical University, Miyagi Cancer Center, Yamagata Prefectural Central Hospital, Tochigi
